3 completed, 1 not yet recruiting, 1 terminated. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Not yet recruiting 1, Terminated 1 |
Follow Influenza Immunization: new trials by email Literature Review of Influenza Immunization trials Research Report on Influenza Immunization
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older IIV-HD (standalone), NVXC19 (EU licensed, standalone), IIV-HD + NVXC19 combination - Immunization, Healthy Volunteers | Phase 3 | Not yet recruiting | Sanofi | 6000 | 2026-11-09 | 2026-10-22 |
| Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years Recombinant influenza vaccine (RIV4), Quadrivalent influenza vaccine (IIV4) - Influenza Immunization | Phase 3 | Terminated | Sanofi Pasteur, a Sanofi Company | 366 | 2022-11-10 | 2025-09-09 |
| Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age. Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH - Influenza Immunization | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1308 | 2022-10-27 | 2025-09-09 |
| Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD), Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD) - Influenza Immunization, Healthy Volunteers | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 2100 | 2020-10-21 | 2025-09-23 |
| Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD), High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation - Influenza Immunization, Healthy Volunteers | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1539 | 2019-10-28 | 2025-09-12 |
Influenza, Human (5)
Infections (5) · Orthomyxoviridae Infections (5) · RNA Virus Infections (5) · Respiratory Tract Diseases (5) · Respiratory Tract Infections (5) · Virus Diseases (5)
Influenza Vaccines (3) · Hemagglutinins (1) · Neuraminidase (1) · Saline Solution (1)
Sanofi Pasteur, a Sanofi Company (4) · Sanofi (1)
Poland (3) · Spain (2) · United States (2) · Belgium (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Netherlands (1)
2019 (1)